Thomas Fuller / SOPA Images / LightRocket via Getty Images Key Takeaways Charles River Laboratories made changes in its board and announced a strategic review as it faced pressure from Elliott Investment Management. The medical testing firm will add four new board members, and four current members won't run for reelection. Elliott, the company's biggest shareholder, called the steps being taken "the right ones" to boost the value of Charles River. Charles River Laboratories (CRL) shares soared 16% to lead S&P 500 gainers Wednesday morning as the medical testing company announced a shakeup of its board and launched a strategic review of its operations after being pressured by activist investor Elliott Investment Management. Charles River's board agreed to bring on four new directors, as four current members won't seek reelection. Following the changes, which will come at the May 20 annual meeting, the company will have 11 directors, nine of whom independent. The board also authorized "a comprehensive strategic review and evaluation of Charles River’s business and prospects, including an examination of various alternatives to enhance long-term stockholder value." In addition, Charles River said that it has signed a cooperation deal with Elliott, its largest shareholder, in which Elliott "has agreed to customary standstill, voting, confidentiality, and other provisions." 'Substantial Opportunity' Exists to Unlock Value, Elliott Partner Says Partner Marc Steinberg noted that Elliott believes Charles River's "current value is significantly disconnected from its underlying potential," and a "substantial opportunity" exists to unlock that value. Steinberg explained that these new moves by the company "are the right ones." Shares of Charles River Laboratories sank to a more than six-year low last month, and even with today's gains they remain down more than 25% year-to-date. TradingView Read the original article on Investopedia View Comments
Charles River Labs Stock Soars as Firm Shakes Up Board, Launches Review
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...